The EPS miss and widening loss are tempered by a strong cash runway and positive pipeline data. Watch for SKYLINE Part B topline results in Q3 2027 and initiation of pivotal HS studies in 2027 as key catalysts.
Drugs in focus
SYRE drug pipeline →SPY002
▲ Bullish Named in this press release- Impact
- Phase
- Phase 2
- Time to market
- SPY002 is in Phase 2 development. If SKYLINE Part B (combination) data in Q3 2027 is positive, a Phase 3 program would follow. Assuming successful development, potential approval would be several years away, likely in the 2029-2031 timeframe.
- Next catalyst
- None dated
What to watchThe next hard catalyst for SPY002 is the SKYLINE Part B combination-therapy topline data expected in Q3 2027. Positive data would validate Spyre's combination strategy and could drive significant upside; negative data would undermine the entire platform thesis. The company also has SPY072 SKYWAY data and SKYLIGHT HS data as additional catalysts in late 2027/early 2028.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 4 $99.04entry
- T+1 · 12d ago −2.47%α +1.94% · $96.59
- T+5 · 6d ago +7.86%α +8.77% · $106.82
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Spyre Therapeutics reported Q3 2026 net loss of $96.1M ($0.94 per common share), wider than the $11.2M loss a year ago, driven by increased R&D spending. The company highlighted positive Phase 2 data for its IBD pipeline and plans to advance TL1A programs into pivotal HS studies, with $1.47B pro forma cash providing runway into H2 2029. The EPS of -$0.94 is below the consensus estimate of -$0.84, representing a miss.
Key Financial Metrics
Key Facts
- Q3 2026 net loss of $96.1M vs $11.2M in Q3 2025
- EPS of -$0.94 per common share vs consensus -$0.84
- R&D expenses rose to $89.2M from $45.2M YoY
- Pro forma cash $1.47B with runway into H2 2029
- Positive Phase 2 data for SPY001, SPY002, SPY003 in IBD
- SPY072 failed PsA and axSpA endpoints, will not advance in rheumatic disease
- October 2026 public offering raised $378M net proceeds
- SKYLINE Part B enrollment ahead of schedule, topline data expected Q3 2027
Financial Impact
Net loss widened by $84.9M YoY to $96.1M; EPS miss of $0.10 vs consensus
Risk Factors
- SPY072 failed in PsA and axSpA, limiting rheumatic disease opportunity
- R&D spend is accelerating with no near-term revenue
- Dilution from October 2026 offering (11.8M shares added)
- Clinical-stage biotech with no approved products
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3394730 |
Track record
36 reports on SYRE
8 of 12 bullish or bearish reports moved the stock their way by T+60. Best: +54.27% at T+60 after the Apr 13, 2026 report. 14 of 20 went positive at some point.
Filters
- Nov 3, 202613d ago 8-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Bearish 5/10 Viewing Entry $99.04 Now $99.37 −0.33% settles Feb 2
- Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 9, 20265w ago SC 13D/A Neutral 3/10 Entry $85.90 Now $99.37 +15.68% settles Jan 7
- Oct 7, 20265w ago 8-K Bearish 5/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 6, 20265w ago 424B5 Bearish 6/10 Entry $80.85 Now $99.37 −22.91% settles Jan 4
- Oct 5, 20266w ago Press Release Bearish 6/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago 424B5 Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 5, 20266w ago Press Release Bearish 5/10 Entry $80.11 Now $99.37 −24.04% settles Dec 31
- Oct 2, 20266w ago Insider Cluster Bearish 4/10 Entry $92.72 Now $99.37 −7.17% settles Dec 30
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers